Compositions and methods for the treatment or prevention of chemoresistant neoplasia
The invention generally features compositions and methods useful for the treatment and diagnosis of a neoplasia in a subject. In particular, the invention provides therapeutic compositions that decrease the expression of an Nfr2 nucleic acid molecule or polypeptide for the treatment of a neoplasia, such as a chemoresistant neoplasia, in a subject.
1. A method for diagnosing a subject as having chemoresistant non-small cell lung cancer, the method comprising obtaining a biological sample from the subject, detecting a mutation in Keap1 and detecting an increase in the expression of Nrf2, GSH, GST, and NQO1 polypeptide marker molecules in the sample relative to the expression of—Nrf2, GSH, GST, and NQO1 polypeptide markers in a normal tissue, thereby diagnosing the subject as having chemoresistant non-small cell lung cancer.
2. A method for diagnosing a subject as having non-small cell lung cancer, the method comprising
obtaining a biological sample from the subject, detecting a mutation in Keap1 and detecting an increase in the levels of Nrf2, GSH, GST, and NQO1 polypeptide markers in the biological sample relative to the levels present in a normal control tissue, thereby diagnosing the subject as having non-small cell lung cancer.
3. The method of claim 2 , wherein the levels of the markers are determined in an immunological assay.
4. The method of claim 3 , wherein the immunological assay is an enzyme-linked immunosorbent assay (ELISA), radioimmune assay (RIA), Western blot assay, slot blot assay, or microchip assay.